
Investors
Information for investors including Annual Reports, Financial Calendar, Shareholders' Information and Quarterly Trading Result.
Key information
Investing in GSK
Our business is focused around the delivery of three strategic priorities which aim to increase growth, reduce risk and improve our long-term financial performance. These priorities are: grow a balanced global business, deliver more products of value, and simplify the operating model. Operating responsibly and ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.
Grow a balanced business
We have been creating a more balanced business and product portfolio, capable of delivering sustainable sales and earnings growth and improved returns to shareholders.
This is centred on our three business areas of Pharmaceuticals, Vaccines and Consumer Healthcare.
Deliver more products of value
We have changed our R&D organisation so that it is better able to sustain a pipeline of products that offer valuable improvements in treatment for patients and healthcare providers. This is underpinned by a focus on improving productivity and rates of return in R&D.
Simplify the operating model
As our business continues to change shape, we are transforming how we operate so that we can reduce complexity and become more efficient. This frees up resources to reinvest elsewhere in the business, or return to shareholders wherever we see the most attractive returns.
Responsible business
Being a responsible business is central to our strategy, and how we deliver success is just as important as what we achieve. Ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.
General Meetings & Annual Reports
Information for shareholders including Notices, Annual Reports and Quarterly Trading Result
Notices
Annual Reports
Financial Calendar
Scheduled timeline for the release of Financial Results
Event | Date |
---|---|
Audited Financial Statement | March |
Quarter 1 Un-audited Results | April |
Quarter 2 Un-audited Results | July |
Quarter 3 Un-audited Results | October |
Shareholder information
Contact details
Investors and Analysts
Investors and Analysts should contact :
Corporate Communications
GlaxoSmithKline Consumer Nigeria PLC
1, Industrial Avenue, Ilupeju, Lagos
Tel: +234-1-2711000, +234-1-3249000
E-mail: ng.investors@gsk.com
Website: www.ng.gsk.com
Individual Shareholders should contact:
The Company Secretary
GlaxoSmithKline Consumer Nigeria PLC
1, Industrial Avenue, Ilupeju, Lagos
Tel: +234-1-2711000, +234-1-3249000
E-mail: ng.investors@gsk.com
Website: www.ng.gsk.com
Registrars and Transfer Office
Greenwich Registrars & Data Solutions Limited (formerly GTL Registrars)
No. 274, Muritala Muhammed Way,
Yaba, Lagos State.
Tel: +234-1-2917747, +234-1-2917745, +234-1-2917714
External Auditors
Akintola Williams Deloitte
Civic Towers Ozumba Mbadiwe Road
Victoria Island
Lagos State
Tel: +234 -1-2717800